Details for Patent: 10,300,087

Which drugs does patent 10,300,087 protect, and when does it expire?

Patent 10,300,087 protects LOKELMA and is included in one NDA.

This patent has twenty-five patent family members in nineteen countries.

Summary for Patent: 10,300,087

Patent landscape, scope, and claims:

Title:	Extended use zirconium silicate compositions and methods of use thereof
Abstract:	The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.
Inventor(s):	Keyser; Donald Jeffrey (Southlake, TX), Guillem; Alvaro F. (Lantana, TX)
Assignee:	ZS PHARMA, INC. (Coppell, TX)
Application Number:	15/421,132
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,300,087
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 10,300,087

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No	10,300,087			Y		TREATMENT OF HYPERKALEMIA IN ADULTS
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018		RX	Yes	Yes	10,300,087			Y		TREATMENT OF HYPERKALEMIA IN ADULTS

International Family Members for US Patent 10,300,087

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	106369
Australia	2016338753
Brazil	112018007189